Validation of the all-comers design: Results of the TARGET-AC substudy-Reference-Cited by-同舟云学术

Validation of the all-comers design: Results of the TARGET-AC substudy

Published:2020-03 Issue: Volume:221 Page:148-154
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

G Toth Gabor,Lansky Alexandra,Baumbach Andreas,Kelbæk Henning,van Royen Niels,Holmvang Lene,Janssens Luc,Brugaletta Salvatore,Barbato Emanuele,Maillard Luc,Kiemeneij Ferdinand,Naber Christoph Kurt,Pucher Felix,Laursen Peter Nørkjær,Ameloot Koen,Robles Carlos,Milkas Anastasios,Sevilla Jose,Jensen Christoph,Wijns William

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. Is the randomized clinical trial the gold standard of research?;Simon;J Androl,2001

2. Understanding controlled trials. Why are randomised controlled trials important?;Sibbald;BMJ,1998

3. Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A; TARGET All Comers Investigators. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet. 2018 Sep 29;392(10153):1117–1126. doi: https://doi.org/10.1016/S0140-6736(18)31649-0.

4. Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987–997. doi: https://doi.org/10.1016/S0140-6736(18)32467-X.

5. Colombo A, Chandrasekhar J, Aquino M, Ong TK, Sartori S, Baber U, Lee M, Iniguez A, Hajek P, Borisov B, Atzev B, Den Heijer P, Coufal Z, Hudec M, Mates M, Snyder C, Moalem K, Morrell D, Elmore F, Rowland S, Mehran R; MASCOT Investigators. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 May 15;283:67–72. doi: https://doi.org/10.1016/j.ijcard.2019.01.053.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review;Systematic Reviews;2024-04-23